Randomized, Double-Blind, Placebo-Controlled Ph2 BLU-285 in Indolent and Smoldering Systemic

Clinical Trial Grant

Duke Scholars

Principal Investigator Lindsay Anne Magura Rein Medicine, Hematologic Malignancies and Cellular Therapy

Awarded By

Blueprint Medicines Corporation

Start Date

May 5, 2021

End Date

May 14, 2026

Awarded By

Blueprint Medicines Corporation

Start Date

May 5, 2021

End Date

May 14, 2026